1. Home
  2. NMFC vs SPRY Comparison

NMFC vs SPRY Comparison

Compare NMFC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Mountain Finance Corporation

NMFC

New Mountain Finance Corporation

HOLD

Current Price

$7.81

Market Cap

796.4M

Sector

Finance

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$8.72

Market Cap

829.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMFC
SPRY
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
796.4M
829.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NMFC
SPRY
Price
$7.81
$8.72
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$8.63
$40.00
AVG Volume (30 Days)
1.4M
959.2K
Earning Date
01-01-0001
06-12-2026
Dividend Yield
16.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$84,278,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$91.00
P/E Ratio
$12.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.52
$6.66
52 Week High
$11.20
$18.63

Technical Indicators

Market Signals
Indicator
NMFC
SPRY
Relative Strength Index (RSI) 37.85 41.71
Support Level $7.52 $8.61
Resistance Level $8.28 $10.44
Average True Range (ATR) 0.23 0.46
MACD 0.02 -0.02
Stochastic Oscillator 39.71 40.74

Price Performance

Historical Comparison
NMFC
SPRY

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: